Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study

We report results of our prospective pilot trial evaluating safety/feasibility of peritransplantation ruxolitinib for myelofibrosis treatment. Primary objectives were to determine safety and maximum tolerated dose (MTD) of ruxolitinib. Ruxolitinib was administered at 2 dose levels (DLs) of 5 and 10...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Haris, Tsai, Ni-Chun, Synold, Timothy, Mokhtari, Sally, Tsia, Weimin, Palmer, Joycelynne, Stiller, Tracey, Al Malki, Monzr, Aldoss, Ibrahim, Salhotra, Amandeep, Rahmanuddin, Syed, Pullarkat, Vinod, Cai, Ji-Lian, Stein, Anthony, Forman, Stephen J., Marcucci, Guido, Mei, Matthew, Snyder, David S., Nakamura, Ryotaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905711/
https://www.ncbi.nlm.nih.gov/pubmed/34581764
http://dx.doi.org/10.1182/bloodadvances.2021005035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905711/
https://www.ncbi.nlm.nih.gov/pubmed/34581764
http://dx.doi.org/10.1182/bloodadvances.2021005035

Ejemplares similares